Intervention

LCZ696

ClinicalTrials.gov intervention label

Clinical trials32
Recruiting0
Common conditions19
Lead sponsors shown3

Clinical trials

32 shown
An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.NCT03909295 · 2019-05-07
TERMINATED
COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart FailureNCT03917459 · 2019-04-16
COMPLETED
Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1NCT03738878 · 2018-11-15
TERMINATED
EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)NCT02816736 · 2017-03-02
COMPLETED
Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection FractionNCT02884206 · 2016-11-23
COMPLETED
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart FailureNCT02678312 · 2016-11-03
COMPLETED
Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.NCT02768298 · 2016-07-12
COMPLETED
Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation EventNCT02661217 · 2016-02-12
COMPLETED
Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection FractionNCT02468232 · 2015-06-15
COMPLETED
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection FractionNCT02226120 · 2014-10-16
COMPLETED
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection FractionNCT01920711 · 2014-07-18
COMPLETED
Study of the Efficacy and Safety of LCZ696 Alone and in Combination With Amlodipine in Patients With HypertensionNCT01865188 · 2014-04-01
WITHDRAWN
Safety and Tolerability of Initiating LCZ696 in Heart Failure PatientsNCT01922089 · 2013-11-01
COMPLETED
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to OlmesartanNCT01876368 · 2013-09-01
COMPLETED
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential HypertensionNCT01785472 · 2013-04-01
COMPLETED
Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With HypertensionNCT01692301 · 2012-12-01
COMPLETED
Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive SubjectsNCT01631864 · 2012-10-01
COMPLETED
Evaluation of Drug-drug Interaction Between LCZ696 and Sildenafil in Subjects With Mild to Moderate HypertensionNCT01601470 · 2012-09-01
COMPLETED
Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive HypertensionNCT01681576 · 2012-08-01
COMPLETED
Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to AmlodipineNCT01663233 · 2012-08-01
COMPLETED
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential HypertensionNCT01615198 · 2012-08-01
COMPLETED
Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive PatientsNCT01646671 · 2012-07-01
COMPLETED
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential HypertensionNCT01599104 · 2012-06-01
COMPLETED
Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal DysfunctionNCT01593787 · 2012-05-01
COMPLETED
Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy VolunteersNCT01353508 · 2011-03-01
COMPLETED
An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic HypertensionNCT01281306 · 2011-01-01
COMPLETED
A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential HypertensionNCT01256411 · 2010-11-01
COMPLETED
Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential HypertensionNCT01193101 · 2010-08-01
COMPLETED
LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection FractionNCT00887588 · 2009-11-01
COMPLETED
Safety/Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) of LCZ696 in Patients With Stable Heart FailureNCT00913653 · 2009-05-01
COMPLETED
Efficacy and Safety of LCZ696A in Patients With Essential HypertensionNCT00549770 · 2007-09-01
COMPLETED
Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)NCT02389933
NO_LONGER_AVAILABLE

Common conditions

Hypertension8Essential Hypertension5Heart Failure3Chronic Heart Failure With Reduced Ejection Fraction2Heart Failure With Reduced Ejection Fraction2Heart Failure With Reduced Ejection Fraction (HF-rEF)2Chronic Heart Failure1Chronic Heart Failure (CHF)1Concurrent Obesity1Erectile Dysfunction1Heart Failure With Preserved Ejection Fraction1Heart Failure With Preserved Ejection Fraction (HFpEF)1Heart Failure, Systolic1Hypertension With Renal Dysfunction1Mild to Moderate Hypertension1Pediatric Heart Failure1Salt-sensitive Hypertension1Severe Hypertension1Systolic Hypertension1

Trial status mix

COMPLETED28
TERMINATED2
NO_LONGER_AVAILABLE1
WITHDRAWN1

Phase mix

PHASE315
PHASE213
PHASE44

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.